Nutrition support teams (NST) in a variety of public and private US hospitals were surveyed in the spring of 1983. A mailed questionnaire elicited information from 521 previously identified teams. The intent was to survey the characteristics of hospitals with NST, the structure and function of NST and the attitudes of coworkers regarding NST. The questionnaire was designed to facilitate individual team communication of successes and admonitions regarding team initiation and function. Nutrition support teams from 267 of 521 (51.6%) hospitals responded. Teams, multidisciplinary in composition, were located most frequently in 200 to 500-bed private, nonprofit hospitals. Financial arrangements and the scope of service rendered varied. Attitudes about NST reflected some problems with attending physicians' skepticism, rivalry, and ignorance. Other hospital professionals' attitudes were reported as supportive with reservations. Comments, penned by 90% of respondents, indicated a solid, positive concern for developing nutritional expertise, productive teamwork, and support from fellow care-givers. Generally, NST were found to be in a period of growth and essentially healthy.

Attitude of Health Personnel↗

PubMedDate not supplied

Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Adjustment of dosage of a renally excreted drug (or active metabolite) for patients with severe renal failure still causes some difficulties. It is therefore helpful to select, within a given therapeutic group of drugs, a compound that is particularly safe and easy to use and, if possible, does not require adjustment of dosage. This is 'the drug of choice for renal patients'. Such a drug would ideally meet the following pharmacokinetic criteria: normal urinary excretion less than 30% of the administered dose, predominant biliary and intestinal removal, disposition essentially unaffected by parameters likely to be modified in renal failure (e.g. changes in serum proteins or fluid compartments: receptor sensitivity, etc), and pharmacokinetics not complicated by the formation of active or toxic metabolites that depend on urinary elimination. Above all, the drug should have a wide therapeutic margin and must be free of nephrotoxicity. Examples of drugs of choice for patients with impaired renal function are given for some important therapeutic groups and special emphasis is placed on antibiotics and beta-adrenoceptor blocking agents.

Adrenergic beta-Antagonists↗